In short
This article discusses a clinical trial called SPLEMENGO, which aims to assess the safety and immune response of different meningococcal B vaccine strategies in adults who have undergone spleen removal (asplenia). The study focuses on the use of vaccines containing Neisseria Meningitidis Group B Fhbp Protein Subfamily B, specifically comparing the effectiveness of different vaccination approaches in this vulnerable population.
At a glance
- Study Name
- SPLEMENGO
- Study Type
- Multicenter, randomized, phase III trial
- Primary Objective
- Assess immunogenicity of three meningococcal B vaccine strategies in asplenic adults
- Key Vaccine
- Trumenba (containing Neisseria Meningitidis Group B Fhbp Protein Subfamily A and B)
- Participant Age Range
- 18 to 75 years old
- Main Inclusion Criteria
- Asplenic patients with visible Howell Jolly bodies
- Follow-up Duration
- 4 years from inclusion
- Primary Endpoint
- Proportion of responders one month after completing vaccination
- Safety Assessment
- Clinical and biological safety evaluation for each vaccine strategy
What is NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY B?
NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY B is a component of a vaccine designed to protect against meningococcal disease caused by group B Neisseria meningitidis bacteria. This vaccine is part of a product called Trumenba, which is used to prevent a serious bacterial infection that can cause meningitis (inflammation of the protective membranes covering the brain and spinal cord) and sepsis (a life-threatening response to infection).
Purpose of the Vaccine
The primary purpose of this vaccine is to stimulate the immune system to produce antibodies against group B meningococcal bacteria. These antibodies help protect individuals from developing meningococcal disease if they are exposed to the bacteria in the future. The vaccine is particularly important for people who have had their spleen removed (asplenic patients), as they are at higher risk of severe bacterial infections.
Vaccine Composition
Trumenba contains two main components:
- NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY A: This is one of the two recombinant lipoproteins in the vaccine.
- NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY B: This is the second recombinant lipoprotein in the vaccine.
These proteins are also known as NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT LIPOPROTEIN (RLP2086, SUBFAMILY A) and NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT LIPOPROTEIN (RLP2086, SUBFAMILY B), respectively.
Current Clinical Trial: SPLEMENGO
A clinical trial called SPLEMENGO is currently being conducted to assess the effectiveness and safety of Trumenba and other meningococcal B vaccines in adults without a spleen. Here are some key points about the trial:
- It is a multicenter, randomized, phase III trial.
- The trial aims to evaluate the immunogenicity (ability to provoke an immune response) and safety of three different meningococcal B vaccine strategies.
- The primary objective is to assess the immune response one month after completing the vaccination schedule.
- Secondary objectives include evaluating long-term immunity (up to 48 months), determining factors that influence immune response, and assessing the safety of the vaccines.
Eligibility Criteria for the Trial
To participate in the SPLEMENGO trial, individuals must meet certain criteria. Some key inclusion criteria are:
- Age: 18 to 75 years old
- Asplenic (without a spleen) for at least 2 weeks
- Visible Howell Jolly bodies on blood film (these are abnormal red blood cells that indicate the absence of a functioning spleen)
- Confirmed splenectomy (surgical removal of the spleen)
Some exclusion criteria include:
- Previous meningococcal B vaccination
- Severe acute illness within a week before inclusion
- History of anaphylaxis (severe allergic reaction) after vaccination
- Known allergy to vaccine components
- Recent use of certain medications that may affect the immune system
Vaccine Administration
Trumenba is administered as an intramuscular injection. In the SPLEMENGO trial, participants receive up to three doses of the vaccine over a period of 6 months. The exact dosing schedule may vary depending on the specific vaccine strategy being studied.
Safety Considerations
As with any vaccine, safety is a crucial aspect of the research. The SPLEMENGO trial includes monitoring for both clinical and biological safety of the vaccines. Special attention is given to adults over 65 years of age. Common side effects of vaccines may include pain at the injection site, fatigue, and mild fever, but severe reactions are rare.
Future Research and Data Sharing
The SPLEMENGO trial is designed to provide valuable data on the use of meningococcal B vaccines in asplenic adults. After the study is completed and results are published, individual participant data will be made available to other researchers for further analysis. This data sharing approach aims to maximize the scientific value of the research and potentially lead to additional insights and improvements in meningococcal disease prevention.